CPhI Online

Thermo Fisher to invest more than $475 million this year on capacity and capability expansion

23 Mar 2020

Thermo Fisher Scientific will invest more than USD475 million in 2020 in new capabilities and capacity to meet increasing demand for biologics, cell and gene therapies and drug products, the contract development and manufacturing organisation said Monday.

"We've invested strategically to ensure that lack of capabilities, capacity or supply is never a reason medicines are delayed in reaching patients," said Mike Shafer, president of Thermo Fisher's pharma services business.

Thermo Fisher said a new bioprocessing collaboration centre will open at its St. Louis site, where multiple units will jointly develop bioprocessing products, workflows and services for customers.

The CDMO has already completed a $50 million expansion of the St Louis site, doubling production capacity for biological drug substance development and commercial manufacturing.

Thermo Fisher will also open a new cell therapy development and manufacturing collaboration centre in Princeton, New Jersey, which will come online later this year.

To address increased demand for high-quality sterile/fill finish services, Thermo Fisher said it is also making “unprecedented investments” to scale up its sterile drug development and commercial capabilities globally to cover a full range of dosage forms for sterile injectables.

Through its acquisition of Brammer Bio last year, Thermo Fisher rapidly expanded its viral vector development and manufacturing capabilities, opening a new site in Lexington, Mass. and expanding sites in Cambridge, Mass. and Alachua, Fla.